Let's assume for a moment they announce good results on Dec 5th,... would the company plan a phase 3 trial for same Diabetic patient population that we had in the BETonMACE trial,..?

Can we already tell if the MOA for CD would cover all patients that suffer from CD or are we limited to the Diabetics with low HDL and a recent MACE event, etc,...?

Also will we be able to tell if our drug can be used as a prevention for CD, or must that be another separate phase 3 trial,..?

Thanks!